ClinicalTrials.gg
Not yet recruitingNCT06606561Updated Apr 13, 2026

NANOVAE to Treat Knee Osteoarthritis (KOA)

A Phase 1/2 interventional study of NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF) and 0.9% Sodium Chloride Injection, USP in Knee Osteoarthritis, sponsored by Nova Vita Laboratory. Not yet recruiting at 1 site in United States. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Nova Vita Laboratory · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 153 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.

Planned enrollment
558th of 691
24 · median 72
Started
2026
with 29 others
Phase 1/2
22 of 796
4 open now
Primary completion
2027-04
later than 65 of 152 live
Registered
728th of 796
by date

Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 558th largest by planned enrollment of the 691 interventional ones that give a count, is one of 30 that started in 2026, is one of 22 in phase 1/2, reaches primary completion later than 65 of the 152 other live ones, and was the 728th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:

104 more — sign in →

All 109 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 21 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 796 studies in Osteoarthritis, Knee with a site in United States, or all of them as a file.
02

Study summary

The below summarizes relevant information for investigator(s) to consider the use of Allogenic Human Amniotic Fluid product in a clinical protocol detailing study design and conduct for a phase I/II randomized, double-blinded, placebo-controlled clinical trial to evaluate the safety and potential efficacy of NANOVAE injected intra-articularly in patients suffering from knee osteoarthritis. The IB will be reviewed annually and amended when further information becomes available.

Osteoarthritis (OA) is a degenerative disease of the joints that affects millions of people worldwide, yet its exact causes are not fully understood. Middle-aged to elderly individuals are often the most impacted by OA, which primarily affects the knee, hip, spine, and joints in the fingers. Among these, knee osteoarthritis (KOA) is the most common form, causing pain, stiffness, and reduced functionality, and it is a major contributor to chronic bone and muscle pain. It is also a leading cause of disability in adults who are not living in institutions. Treatment for KOA is challenging due to its resistance to medications, procedures, and surgeries. The primary objective is to alleviate pain and enhance overall function. However, since there is currently no cure for OA, the need for an effective therapy remains urgent. Healthcare professionals often encounter patients whose pain may result from an inflammatory response triggered by injury or disease. Research suggests that regenerative medicine, utilizing techniques like stem cells, platelet-rich plasma (PRP), amniotic fluid, and cytokine modulation, holds promise for treating KOA.

OA is associated with an increase in pro-inflammatory substances such as interleukin (IL)-1, IL-6, tumor necrosis factor-alpha (TNF-α), matrix metalloproteinases (MMPs), nitric oxide (NO), reactive oxygen species (ROS), and cytokine-inducible cyclooxygenase-2 (COX-2). These inflammatory agents affect various cell types within the affected joints, including chondrocytes, osteoblasts, osteoclasts, synoviocytes, and macrophages. Some miRNAs, which are downregulated in OA, have been identified as protective factors. For example, miR-130 helps regulate TNF-α levels, while miR-149 controls several inflammatory cytokines such as IL-1, IL-6, and TNF-α. The breakdown of the cartilage matrix is a key characteristic of OA. MMP-13, a member of the MMP family, plays a significant role in degrading the collagen network during OA development. Several miRNAs, including miR-27b, miR-27a, miR-148a, miR-320, miR-127-5p, and miR-411, are downregulated in OA and target the mRNA of this proteinase. It is important to note that a single miRNA can regulate multiple target genes associated with OA progression. For instance, miR-105 and miR-148, both downregulated in OA, target genes such as Runx2, ADAMTS4, ADAMTS5, ADAMTS7, ADAMTS12, MMP-13, and COL10, implying their potential protective roles.

Several studies have shown a link between certain miRNAs, aging, and the progression of OA. For example, miR-320c is downregulated in aging OA samples and regulates ADAMTS5, suggesting that this miRNA may serve as a protective factor by enhancing chondrogenesis.

Read the detailed description

The investigational product being assessed in this trial is called NANOVAE, which is a biologic derived from human amniotic fluid (HAF) that is allogenic and acellular. HAF contains a wide range of growth factors, cytokines, chemokines, and extracellular vesicles/nanoparticles obtained from perinatal tissue. These components contribute to the regenerative potential of HAF and make it a promising option for regenerative medicine applications, particularly in knee osteoarthritis (KOA). Studies have demonstrated that the extracellular vesicles found in HAF, including exosomes, have the ability to promote chondrogenesis and reduce inflammation, which are crucial processes in reversing the progression of KOA. Additionally, these vesicles have shown to stimulate cartilage regeneration, addressing the impaired cartilage repair typically observed in OA. Therefore, the administration of HAF-derived products has the potential to slow down the degenerative process and promote cartilage repair in patients with KOA. The growth factors and cytokines present in HAF may also help alleviate the inflammatory response observed in the knee joint, a characteristic feature of KOA. These anti-inflammatory properties, combined with the regenerative capabilities of the extracellular vesicles, make HAF an appealing candidate for the treatment of KOA.

Numerous clinical studies registered under ClinicalTrials.gov have provided evidence of the safety and effectiveness of HAF products in joint therapies. The use of HAF for treating OA holds immense potential due to its array of growth factors, anti-inflammatory mediators, and medicinal signaling cells, which continue to undergo rapid advancements. In a non-FDA review study, a double-blinded controlled trial was conducted comparing the treatment of OA with freshly collected amniotic fluid and steroids. The results revealed a significant improvement in the Visual Analog Scale (VAS) after three months of treatment, with continuous improvement in VAS after six months in both groups. However, the group receiving freshly collected amniotic fluid exhibited greater improvement. These findings strongly support the potential of this novel HAF therapy for advanced OA, as it proved to be superior and longer lasting compared to conventional therapies commonly practiced. Further research, both in terms of basic science and clinical investigations, is warranted to gain a better understanding of the anti-inflammatory properties of amniotic fluid and determine the most efficacious amniotic fluid product for symptomatic OA.

NANOVAE is a filtered form of HAF (human amniotic fluid) that utilizes the wide range of nanoparticles, cytokines, and growth factors present in the fluid, which play vital roles in fetal development and maturation. HAF is a rich source of collagen substrates, growth factors, amino acids, polyamines, lipids, carbohydrates, cytokines, and extracellular matrix molecules like hyaluronic acid and fibronectin, as well as cells. These components greatly contribute to tissue protection and repair. Extensive research has demonstrated the antimicrobial, immunomodulatory, and growth-promoting properties of HAF. The antimicrobial, antiviral, and antifungal effects of HAF have been established through the identification of various components such as lysozyme, peroxidase, transferrin, β-lysin, immunoglobulins, and zinc-peptide complexes within the fluid. The immunomodulatory functions of HAF have been observed in its ability to suppress alloreactive responses and downregulate Th1 and Th2 cytokines.

NANOVAE's extracellular vesicle (EV) fraction consists of several cytokines, chemokines, and growth factors that are associated with functions such as host defense, anti-inflammatory response, angiogenesis, and cartilage repair. The concentration of nanoparticles in the final product has been consistently demonstrated through nanoparticle analysis using the ZetaView Quatt nanoparticle analyzer. This analysis reveals a range of particles, with an average mode particle size of 96.4 nM, which aligns with the expected size of exosomes ranging between 50-200 nm in diameter.

Objectives:

Primary Objective: To demonstrate the safety of NANOVAE administered intraarticular in subjects with KOA by measuring the incidence of any of the following treatment-emergent adverse events (TE-AEs) and treatment-emergent serious adverse events (TE-SAEs) within the first 30 days of injection:

Occurrence of adverse events related to the therapy within 30 days of NANOVAE treatment.

Life-threatening event (e.g., stroke or non-fatal pulmonary embolism). Event resulting in persistent or significant disability/incapacity. Event resulting in death.

Secondary Objective: To demonstrate the potential efficacy of NANOVAE by measuring the following clinical response changes from baseline to 12 months after injection. Time Frame: Month 1, 3, 6, and 12 after infusions:

Change in single leg stance test. Change in "Timed Up and Go" test to assess fall risk. Change in Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index (five items for pain, two for stiffness, and seventeen for function).

Change in range of motion, assessed by goniometer measurements. Change in serum and/or synovial biomarkers between the timepoints of Day 0 and the 3-month visit.

Design and Investigational Plan: A total of 24 subjects meeting all inclusion/exclusion criteria will be divided into two groups. Group 1 will be an open-label lead-in phase. Group 2 will be a randomized, double-blinded, placebo-controlled cohort. Group 1 will receive one dose of 2ml of NANOVAE, and Group 2, in a randomized and double-blinded fashion, will receive two doses of 2ml NANOVAE. Neither the patients nor the researchers will know who is getting the placebo and who is getting the NANOVAE; only the product manufacturing staff will be unblinded. The ratio of placebo to NANOVAE is 1:1 for a total of 16 subjects in Group 2. Only the knee with the more severe symptoms of OA will be treated. The allogenic-HAF will be obtained from healthy donors and manufactured by the Nova Vita Laboratories processing lab.

Group 1 (Open Label): A total of eight subjects will be treated to assess safety prior to enrolling Group 2. Safety will be assessed at seven-day intervals for the 8 subjects in Group 1, staggered by 5 days after receiving the dose of NANOVAE.

Dose: 2 mL of NANOVAE on Day 0 containing 1.0 x 10¹¹ to 9.0 x 10¹¹ particles/ml. Product will be administered directly without any dilution.

After these 8 subjects complete the 5-day safety assessment, the safety report will be presented to the DSMB with representative data to determine the safety status of receiving one dose of NANOVAE. Once the treatment of Group 1 has been determined to be safe, the enrollment of Group 2 will begin.

Group 2 (Randomized, double-blinded placebo control): A total of sixteen subjects will be randomized to either receive two doses of NANOVAE via intraarticular injections or receive two doses of a placebo.

Dose: 2 mL of NANOVAE or placebo on Day 0 and Day 15, containing 1 x 10¹¹ particles/ml. The ratio is 1:1 for a total of 16 subjects in Group 2. Product will be administered directly without any dilution.

Sample Size \& Study Population: A total of 24 adult patients will be chosen from the population of adults between the ages of 21 to 75 diagnosed with KOA who meet inclusion criteria.

Route of Administration: Intra-articular Injections.

Study Duration and Study Follow-Up: 12 months total duration:

Day 0 and 15 - Intraarticular Injection and observational follow-up. Days 1 and 7 (after dose of NANOVAE or placebo) - Observational follow-up via phone call, telehealth, or in-person visit.

Months 1, 3, 6, and 12 - Observational follow-up visits per protocol design.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • Knee Osteoarthritis
04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age eligible for study: 21 to 75 years
  2. Gender eligible for study: All
  3. Study subjects must be willing to give written to participate in the study and sign the Health Insurance Portability and Accountability Act (HIPAA) authorization before any study procedures are performed.
  4. Subjects have a diagnosis of OA in at least one knee defined as Grade II or III on Kellgren-Lawrence (K-L) grading scale which is confirmed by posterior-anterior, weight-bearing, fixed flexion radiography with 10o caudal beam angulation.
  5. Subjects with VAS pain score ≥40 mm on screening day will be included.
  6. Subjects had one or more of the following SOC treatments within the previous 12 months will be included:

    1. weight loss
    2. physical therapy
    3. anti-inflammatory medications - oral, injections and topical
  7. (BMI) \< 45kg/m2
  8. Subjects must be available for all specified assessments at the study site through the completion of the study.
  9. For Women of (WOCBP) only, willingness to use FDA-recommended until 6 months post treatment. The FDA-approved and cleared methods for birth control are listed below:

    1. Permanent Sterilization
    2. Long-Acting Reversible Contraceptives (LARC)
    3. Contraceptive Injection
    4. Short-Acting Hormonal Methods
    5. Barrier Methods
    6. Emergency Contraception https://www.fda.gov/consumers/free-publications-women/birth-control
  10. Any male subject must agree to use contraceptives and not donate sperm during the study.
  11. Patient may be eligible for treatment of both knees if criteria is met for both

Exclusion criteria

Exclusion Criteria:

  1. Subjects have evidence of significant and unstable cardiac dysfunction, e.g. acute myocardial infarction and hypertension with uncontrolled blood pressure over 140/90 will be excluded.
  2. Subjects at screening with white blood cell count \< 4 x 109 cells/L, hematocrit \<30%, and \<150 x 109 /L will be excluded.
  3. Subjects with poorly controlled diabetes ( > 7.5 or fasting blood glucose of >200) in last 6 months will be excluded.
  4. Individuals on dialysis or uncontrolled renal disease will be excluded.
  5. Subjects with abnormal hematology, serum chemistry, or urinalysis screening laboratory results will be excluded.
  6. Subjects with history of, or ongoing, disorder that requires treatment with an medication will be excluded.
  7. Subjects had knee surgery on the targeted knee within 12 months prior to screening and /or planned knee surgery during the study will be excluded.
  8. Subjects have a greater than 45 kg/m2 will be excluded.
  9. Subjects whose knee pain is caused by, (i) diffuse edema, extra articular causation (ii) displaced meniscus tear, (iii) full thickness articular cartilage lesion greater than 1 cm in any direction, or (iv) osteochondritis dissecans will be excluded.
  10. Subjects have rheumatoid arthritis, psoriatic arthritis, or have been diagnosed with any other auto-immune disorders that could be the cause of their knee pain will be excluded.
  11. Subjects which have evidence or history of except those who are successfully treated in situ or basal cell skin cancers will not be excluded.
  12. Subjects with a history of clotting disorder, anticoagulation therapy that cannot be stopped as prior to infusion will be excluded.
  13. Subjects have evidence of liver dysfunction manifested as alkaline phosphatase greater than 345 u/L, total greater than 1.65 mg/dL, greater than 275 units/L and/or AST great than 240 units/L will be excluded.
  14. Subjects have or had an active infection requiring systemic antibiotics within 2 weeks on enrollment in the study will be excluded.
  15. Subjects currently taking anticoagulant therapy (excluding Plavix or Aspirin) will be excluded.
  16. Subjects have received an intra-articular hyaluronic acid (HA) or platelet rich plasma (PRP) for the treatment of OA of the target knee within 12 weeks prior to screening will be excluded.
  17. Subjects have used an drug or had surgical intervention within 12 weeks of the study enrollment will be excluded.
  18. Subjects that are unwilling to stop taking prescription or over the counter pain medication for Osteoarthritis for 7 days prior to any visit will be excluded. Subjects will be permitted to take medications for non-osteoarthritis condition (excluding the one's listed under "Concomitant Medication").
  19. Subjects needing or at high risk of requiring systemic during the course of study will be excluded except systemic use of corticosteroid administration for COVID-19 or flare up of non-arthritic condition.

    Complete information of dose and timeframe of the medication use will be documented in case report forms (CRF).

  20. Be a female who is pregnant, nursing, or of while not practicing effective methods.
  21. Subjects who are unable to complete all the testing required for the study will be excluded.
  22. Subjects on active listing (or expected future listing) for transplant of any organ will be excluded.
  23. Be a solid organ transplant recipient. This does not include prior cell-based therapy (>12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting. Have a history of organ or cell transplant rejection.
  24. Subjects with history of drug abuse (illegal "street" drugs except marijuana (If it is legal use in states where patient resides), or prescription medications not being used appropriately for a pre-existing medical condition or alcohol abuse (≥ 5 drinks/day for ˃ 3 months).
  25. Subjects with untreated infection will be excluded. However, patients can be enrolled if have been treated for HIV and the test negative for HIV viral load but still test positive for antibodies.
  26. Subjects with neural or vascular claudication or neurologic disorder including, but not limited to epilepsy, Parkinson\'s disease, dementia, cerebrovascular disease, tumor of the nervous system, and amyotrophic lateral sclerosis will be excluded.
  27. Subjects cannot have had a hyaluronic acid injection within 6 months prior to NANOVAE injection
  28. Subjects cannot have had a cortisone injection within 3 months prior to NANOVAE Injection
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Group 1 (Open Label)

    A total of eight subjects will be treated to assess safety prior to enrolling Group 2. We propose to assess the safety of 8 subjects in Group 1 at seven-day intervals. Each subject in Group 1 will be staggered by 5 days after receiving the dose of NANOVAE. Dose - 2 mL of NANOVAE on day 0 containing 1.0 x 1011 to 9.0 x 1011 particles/ml. Product will be administered directly without any dilution.

    Drug: NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF)

  • Experimental
    Group 2 (Randomized, double blinded placebo control)

    Total of sixteen subjects will be randomized to either receive two doses of NANOVAE via intraarticular injections or receive two doses of a placebo. Dose - 2 mL of NANOVAE or placebo on day 0 and day 15, containing 1 x 1011 particles/ml. The ratio is 1:1 for a total of 16 subjects in the Group 2. Product will be administered directly without any dilution.

    Drug: NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF) · Drug: 0.9% Sodium Chloride Injection, USP

Interventions

  • DrugNANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF)

    A total of 24 subjects meeting all inclusion/exclusion criteria will be divided into two groups. Group 1 will be an open-label lead-in phase. Group 2 will be a randomized, double-blinded, placebo-controlled cohort. Group 1 will receive one dose of 2ml of NANOVAE, and Group 2, in a randomized and double-blinded fashion, will receive two doses of 2ml NANOVAE. Neither the patients nor the researchers will know who is getting the placebo and who is getting the NANOVAE; only the product manufacturing staff will be unblinded. The ratio of placebo to NANOVAE is 1:1 for a total of 16 subjects in Group 2. Only the knee with the more severe symptoms of OA will be treated. The allogenic-HAF

  • In lieu of AF, the saline for injection will be used as a placebo. Vials acquired from the manufacturer is pipetted into glass vials, stoppered, capped, placed in labeled header foil pouches, and sealed. These are transferred to a quarantine freezer to await post-production testing.

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of NANOVAE administered intraarticular in subjects

    To demonstrate the safety of NANOVAE administered intraarticular in subjects with KOA by measuring incidence of any of the following treatment-emergent adverse events (TE-AEs) and treatment-emergent serious adverse events (TE-SAEs) within the first 30 days of injection: * Occurrence of adverse events related to the therapy within 30 days of NANOVAE treatment. * Life-threatening event (e.g., stroke or non-fatal pulmonary embolism). * Event resulting in persistent or significant disability/incapacity. * Event resulting in death.

    Time frame: 30 Days

Secondary outcomes

  1. Change in Single Leg Stance Test

    The Single Leg Stance Test will measure the ability of participants to balance on one leg for a specified duration. The test will be performed with eyes open and closed, and the time participants can maintain balance on a single leg without support will be recorded in seconds. The minimum value is 0 seconds, indicating inability to balance, and there is no fixed maximum value. Higher values indicate a better outcome (i.e., improved balance).

    Time frame: Baseline, Month 1, 3, 6, and 12 after infusions

  2. Change in "Timed Up and Go" Test

    The Timed Up and Go (TUG) Test will assess participants\&#39; mobility and fall risk by measuring the time (in seconds) taken to stand up from a seated position, walk a short distance (approximately 3 meters), turn around, walk back to the chair, and sit down. The test will be timed using a stopwatch. The minimum time is 0 seconds, and no fixed maximum time is specified. Lower values indicate a better outcome (i.e., faster and safer mobility).

    Time frame: Baseline, Month 1, 3, 6, and 12 after infusions

  3. Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

    The WOMAC Index will be used to assess the participants\&#39; pain, stiffness, and physical function. It includes 5 items for pain, 2 for stiffness, and 17 for function, each rated on a scale of 0 to 4 (0 = none, 4 = extreme). The minimum total score is 0, and the maximum total score is 96. Higher scores indicate a worse outcome, meaning increased pain, stiffness, and dysfunction.

    Time frame: Baseline, Month 1, 3, 6, and 12 after infusions

  4. Change in Serum and/or Synovial Biomarkers

    This outcome will track changes in serum and/or synovial fluid biomarkers relevant to inflammation and cartilage degradation. Biomarkers such as interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-α), and matrix metalloproteinases (MMPs) will be measured at baseline and at the 3-month visit. The results will be reported as concentrations (e.g., pg/mL or ng/mL), with lower levels of inflammatory biomarkers indicating a better outcome.

    Time frame: Baseline, Month 1, 3, 6, and 12 after infusions

  5. Change in Range of Motion (ROM)

    Range of Motion will be measured using a goniometer to assess the degree of flexibility and movement in the knee joint. The test will measure both flexion and extension angles in degrees. The minimum ROM is 0 degrees (indicating no movement), and the maximum depends on the individual's ability. Higher values indicate a better outcome (i.e., increased mobility).

    Time frame: Baseline, Month 1, 3, 6, and 12 after infusions

07

Study locations

1 site
  • Bluetail Medical Group
    Chesterfield, Missouri 63005, United States
08

References and documents

Publications

  • Kohn MD, Sassoon AA, Fernando ND. Classifications in Brief: Kellgren-Lawrence Classification of Osteoarthritis. Clin Orthop Relat Res. 2016 Aug;474(8):1886-93. doi: 10.1007/s11999-016-4732-4. Epub 2016 Feb 12. No abstract available. PubMed 26872913 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Apr 2027, 6 months later.

Of 39 phase 1/2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2024
First posted
Sep 23, 2024
StartEst.
Oct 1, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06606561
Lead sponsor
Nova Vita Laboratory
Responsible party
Sponsor
First posted
Sep 23, 2024
Start date
Oct 1, 2026 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Apr 13, 2026

Study contacts

David Crane, MD
Contact
David@novavitalabs.com
(636) 778-2900
Trillitye Paullin, PhD
Contact
Trill@novavitalabs.com
(984) 569-2483

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Chloride

Start the discussion